|
  
- 积分
- 97
- 威望
- 97
- 包包
- 3142
|
本帖最后由 bobo 于 2009-6-28 08:34 编辑
" c6 x" Y. n+ P+ }, U& i' C1 ?- r2 R' u* \0 a9 R
表观遗传学与干细胞——2009年亚洲生物高峰论坛录制(音频mp3)
/ C" x" S/ k6 v
* }! m. U: Q0 K3 |9 C$ _+ Q$ ^; X- y# h2 S& x! W @7 x& o
) j- d; l$ F3 i( Q
回复为ppt
1 I( k" o1 u; H摘要：
2 q% Q: V/ A7 ~1 s2 Y
8 F4 V- F0 J4 R7 n X/ U6 G m/ }Hongkui Deng
/ N0 @- a1 |: U. [% ]! y2 t% O4 Z- E% p$ q, H3 P4 d
Laboratory of Stem Cell and Generative Biology, College of Life Sciences, Peking University, Beijing 100871, China.# N' G* B1 C, }; a9 J$ k/ W
( X! F6 R, K+ s5 mHuman pluripotent stem cells represent a potentially unlimited source of functional pancreatic endocrine lineage cells. We established a new highly efficient approach to induce human embryonic stem （ES） cells and induced pluripotent stem （iPS） cells to differentiate into mature insulin-producing cells in a chemical-defined culture system. The differentiated cells obtained by this approach comprised nearly 25% insulin-positive cells as assayed by flow cytometry analysis, which released insulin/C-peptide in response to glucose stimuli in a manner comparable to that of adult human islets. Most of these insulin-producing cells co-expressed mature beta cell-specific markers such as NKX6-1 and PDX1, indicating a similar gene expression pattern to adult islet beta cells in vivo. This work provides a new model to study the mechanism of human pancreatic specialization and maturation in vitro, and enhances the possibility of utilizing patient-specific iPS cells for the treatment of diabetes# o* k; Y' D3 C# z
# b0 `' _: }$ c0 ?3 o! a7 r9 q回复为ppt
- Q2 Z: o5 G/ Q* ]% L u( t* B. u6 _
, f; j, B# t! L: |8 ?8 I. n$ W1 }
+ o! \! h a8 L- o' t: _
+ t: Y0 _5 s+ m; t1 o; Y2 x! Q7 x$ @) J# H |
附件: 你需要登录才可以下载或查看附件。没有帐号？注册
|
发表于 2009-6-28 08:19
发表于 2009-8-7 16:10
